Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.69 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.45 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2399935 | 0.83 | HTT (0.96) | HTTALDH1A1TSHRSMN1; SMN2CYP2C9 | |
| SCHEMBL27606796 | 0.83 | HTT (0.47) | HTTSIGMAR1ALDH1A1SMN1; SMN2CYP2D6 | |
| SCHEMBL21882079 | 0.83 | SMN1; SMN2 (0.67) | HTTSIGMAR1ALDH1A1SMN1; SMN2CYP2D6 | |
| SCHEMBL1721295 | 0.83 | CYP2D6 (0.67) | HTTSMN1; SMN2CYP2C9CYP2C19POLB | |
| SCHEMBL3214201 | 0.82 | HPGDS (0.49) | HTTSIGMAR1HDAC3HDAC1HDAC2 | |
| N-Piperidinobenzamide SCHEMBL696161 | 0.81 | HTT (1.00) | HTTALDH1A1TSHRSMN1; SMN2CYP2C9 | |
| SCHEMBL9282775 | 0.81 | HTT (1.00) | HTTALDH1A1TSHRSMN1; SMN2CYP2C9 | |
| Bromide SCHEMBL7777483 | 0.81 | CYP2D6 (0.65) | HTTSMN1; SMN2CYP2C9CYP2C19POLB | |
| SCHEMBL4538968 | 0.81 | ALDH1A1 (0.56) | HTTALDH1A1TSHRSMN1; SMN2POLB | |
| Hydrochloric Acid SCHEMBL3216407 | 0.81 | HPGDS (0.48) | HTTSIGMAR1SMN1; SMN2POLBHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106659765-B | Use of dianhydrogalactitol and analogs or derivatives thereof for treating non-small cell lung cancer and ovarian cancer | 德玛医药 | 2021-08-13 | — | — | CN | disclosed |
| US-9187497-B2 | Substituted pyrido[3,2-e]pyrrolo[1,2-a]pyrazines as inhibitors of poly(ADP-ribose)polymerase (PARP) | TAKEDA PHAMACEUTICAL COMPANY LIMITED (JP) | 2015-11-17 | — | — | US | disclosed |
| US-8980902-B2 | Poly (ADP-ribose) polymerase (PARP) inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-03-17 | — | — | US | disclosed |
| US-20150031652-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-01-29 | — | — | US | disclosed |
| US-8822470-B2 | Substituted pyrido[2,3-b]pyrazines | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-02 | — | — | US | disclosed |
| US-20140024654-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-23 | — | — | US | disclosed |
| US-20130274239-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2013-10-17 | — | — | US | disclosed |
| US-8541417-B2 | Poly (ADP-ribose) polymerase (PARP) inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-09-24 | — | — | US | disclosed |
| US-8450323-B2 | Substituted derivatives of pyrido[3,2-e][1,4]thiazino[4,3-a]pyrazine and pyrido[3,2-e][1,4]oxazino[4,3-a]pyrazine | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-28 | — | — | US | disclosed |
| EP-2459561-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2012-06-06 | — | — | EP | disclosed |
| US-20100190763-A1 | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-29 | — | — | US | disclosed |
| US-20100130485-A1 | Cyclopropyl Amines as Modulators of the Histamine H3 Receptor | JANSSEN PHARMACEUTICA NV (BE) | 2010-05-27 | — | — | US | disclosed |
| EP-1948607-B1 | CYCLOPROPYL AMINES AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2010-04-07 | — | — | EP | disclosed |
| US-7687499-B2 | Cyclopropyl amines as modulators of the histamine H3 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2010-03-30 | — | — | US | disclosed |
| EP-1948607-A2 | CYCLOPROPYL AMINES AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | Janssen Pharmaceutica, N.V. (BE) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007035425-A2 | CYCLOPROPYL AMINES AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-29 | — | — | WO | disclosed |
| US-20070066821-A1 | CYCLOPROPYL AMINES AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-03-22 | — | — | US | disclosed |
| US-20040235855-A1 | Phospholipase C inhibitors for use in treating inflammatory disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-11-25 | — | — | US | disclosed |
| WO-2004087685-A2 | PHOSPHOLIPASE C INHIBITORS FOR USE IN TREATING INFLAMMATORY DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-10-14 | — | — | WO | disclosed |
| EP-0704439-B1 | NOVEL INTERMEDIATE FOR SYNTHETIC USE AND PROCESS FOR PRODUCING AMINOPIPERAZINE DERIVATIVE | FUJISAWA PHARMACEUTICAL CO (JP) | 2001-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190763-A1 | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors | PARP1, PARP3, PARP2 | HTT 805/4885SIGMAR1 3322/4885HSD17B10 2701/4885 |
| US-20070066821-A1 | CYCLOPROPYL AMINES AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | HRH3, HRH4, HRH2 | HTT 619/4885SIGMAR1 169/4885HSD17B10 3998/4885 |
| US-20150031652-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | PARP1, PARP3, PARP2 | HTT 805/4885SIGMAR1 3322/4885HSD17B10 2701/4885 |
| US-20100130485-A1 | Cyclopropyl Amines as Modulators of the Histamine H3 Receptor | HRH3, HRH4, HRH2 | HTT 619/4885SIGMAR1 169/4885HSD17B10 3998/4885 |
| US-20140024654-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | PARP1, PARP2, PARP3 | HTT 2110/4885SIGMAR1 4478/4885HSD17B10 1655/4885 |
| US-20130274239-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | PARP1, PARP3, PARP2 | HTT 805/4885SIGMAR1 3322/4885HSD17B10 2701/4885 |
| US-20040235855-A1 | Phospholipase C inhibitors for use in treating inflammatory disorders | PLA2G4C, PLA2G4B, PLA2G5 | HTT 4808/4885SIGMAR1 2254/4885HSD17B10 1403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.